A proteomic analysis of adult rat bone reveals the presence of cartilage/chondrocyte markers

Journal of Cellular Biochemistry

Volumn 101, Issue 2, 2007, Pages 466-476

  Schreiweis, Melissa A ^a   Butler, Jon P ^a   Kulkarni, Nalini H ^a   Knierman, Michael D ^a   Higgs, Richard E ^a   Halladay, David L ^a   Onyia, Jude E ^a   Hale, John E ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

Bone matrix proteins; Endochondral ossification; LC MS; Proteomics

Indexed keywords

AGGRECAN; CELL MARKER; COLLAGEN TYPE 1; COLLAGEN TYPE 2; OSTEOCALCIN; OSTEOPONTIN; OSTEOREGULIN; PROTEIN; SIALOPROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BONE MATRIX; CARTILAGE; CARTILAGE CELL; CONTROLLED STUDY; DIAPHYSIS; EXTRACELLULAR MATRIX; FEMALE; MASS SPECTROMETRY; METAPHYSIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEOMICS; RAT; VALIDATION STUDY; WESTERN BLOTTING;

AGGRECANS; ANIMALS; BIOLOGICAL MARKERS; BONE AND BONES; BONE MATRIX; CARTILAGE; CHONDROCYTES; COLLAGEN TYPE II; FEMALE; MOLECULAR SEQUENCE DATA; PROTEOME; RATS; RATS, SPRAGUE-DAWLEY;

RATTUS;

EID: 34247889970     PISSN: 07302312     EISSN: 10974644     Source Type: Journal    
DOI: 10.1002/jcb.21196     Document Type: Article

References (53)

1. Alford AI, Hankenson KD. 2006. Matricellular proteins: Extracellular modulators of bone development, remodeling, and regeneration. Bone 38(6):749-757.
2. Andress DL. 2001. IGF-binding protein-5 stimulates osteoblast activity and bone accretion in ovariectomized mice. Am J Physiol Endocrinol Metab 281:E283-E288.
3. Armstrong LC, Bornstein P. 2003. Thrombospondins 1 and 2 function as inhibitors of angiogenesis. Matrix Biol 22:63-71.
4. Atti E, Boskey AL, Canalis E. 2005. Overexpression of IGF-binding protein 5 alters mineral and matrix properties in mouse femora: An infrared imaging study. Calcif Tissue Int 76:187-193.
5. Bauss F, Lang K, Dony C, Kling L. 2001. The complex of recombinant human insulin-like growth factor-I (rhIGF-I) and its binding protein-5 (IGFBP-5) induces local bone formation in murine calvariae and in rat cortical bone after local or systemic administration. Growth Horm IGF Res 11:1-9.
6. Behnam K, Murray SS, Whitelegge JP, Brochmann EJ. 2002. Identification of the molecular chaperone alpha B-crystallin in demineralized bone powder and osteoblast-like cells. J Ortho Res 20:1190-1196.
7. Benjamini Y, Hochberg Y. 1995. Controlling the false discovery rate: A practical and powerful approach to multiple testing. J Royal Stat Soc 57:289-300.
8. Chambers MG, Kuffner T, Cowan SK, Cheah KS, Mason RM. 2002. Expression of collagen and aggrecan genes in normal and osteoarthritic murine knee joints. Osteoarthritis Cartilage 10:51-61.
9. Conrads KA, Yu L-R, Lucas DA, Zhou M, Chan KC, Simpson KA, Schaefer CF, Issaq HJ, Veenstra TD, Beck GR, Jr., Condars TP. 2004. Quantitative proteomic analysis of inorganic phosphate-induced murine MC3T3-E1 osteoblast cells. Electrophoresis 25:1342-1352.
10. Conrads KA, Yi M, Simpson KA, Lucas DA, Camalier CE, Yu L-R, Veenstra TD, Stephens RM, Conrads TP, Beck GR, Jr. 2005. A combined proteome and microarray investigation of inorganic phosphate-induced pre-osteoblast cells. Mol Cell Proteomics 4:1284-1296.
11. Craig R, Beavis RC. 2003. A method for reducing the time required to match protein sequences with tandem mass spectra. Rapid Commun Mass Spectrom 17:2310-2316.
12. Czupalla C, Mansukoski H, Pursche T, Kraise E, Hoflack B. 2005. Comparative study of protein and mRNA expression during osteoclastogenesis. Proteomics 5:3868-3875.
13. Devlin RD, Du Z, Buccilli V, Jorgetti V, Canalis E. 2002. Transgenic mice overexpressing insulin-like growth factor binding protein-5 display transiently decreased osteoblastic function and osteopenia. Endocrinology 143: 3955-3962.
14. Durant D, Pereira RMR, Canalis E. 2004. Overexpression of insulin-like growth factor binding protein-5 decreases osteoblastic function in vitro. Bone 35:1256-1262.
15. Eng JK, McCormack AL, Yates JR. 1994. An approach to correlate tandem mass spectral data of peptides with amino acid sequences in a protein database. J Am Soc Mass Spectrom 5:976-989.
16. Fan Y, Liu J, Wang S, Wang H, Shi F, Xiong L, He W, Peng X. 2005. Functional proteome of bones in rats with osteoporosis following ovariectomy. Life Sci 76:2893-2901.
17. Felsenberg D, Boonen S. 2005. The bone quality framework: Determinants of bone strength and their interrelationships, and implications for osteoporosis management. Clin Therapeutics 27:1-11.
18. Garnero P, Borel O, Gineyts E, Duboeuf F, Solberg H, Bouxsein ML, Christiansen C, Delmas PD. 2006. Extracellular post-translational modifications of collagen are major determinants of biomechanical properties of fetal bovine cortical bone. Bone 38:300-309.
19. Gieffers C, Engelhardt W, Brenzel G, Matsuishi T, Frey J. 1993. Receptor binding of osteoblast-specific factor 1 (OSF-1/HB-GAM) to human osteosarcoma cells promotes cell attachment. Eur J Cell Biol 62:352-361.
20. Higgs RE, Knierman MD, Freeman AB, Gelbert LM, Patel ST, Hale JE. 2006. J Proteom Res (submitted).
21. International Protein Index, European Bioinformatics Institute. 2005. http://www.ebi.ac.uk/IPI/IPIhelp.html.
22. Kersey PJ, Duarte J, Williams A, Karavidopoulou Y, Birney E, Apweiler R. 2004. The International Protein Index: An integrated database for proteomics experiments. Proteomics 4:1985-1988.
23. Kim SH, Jun S, Jang HS, Lim SK. 2005. Identification of parathyroid hormone-regulated proteins in mouse bone marrow cells by proteomics. Biochem Biophys Res Commun 330:423-429.
24. Kubota K, Wakabayashi K, Matsoka T. 2003. Proteome analysis of secreted proteins during osteoclast differentiation using two different methods: Two-dimensional electrophoresis and isotope-coded affinity tags analysis with two-dimensional chromatography. Proteomics 3: 616-626.
25. Kulkarni NH, Wei T, Kumar A, Dow ER, Stewart TR, Shou J, N'cho M, Sterchi DL, Gitter BD, Higgs RE, Halladay DL, Engler T, Martin TJ, Bryant HU, Ma YL, Onyia JE. Submitted. Changes in osteoblast, chondrocyte, and adipocyte lineages mediate the bone anabolic actions of PTH and small molecule GSK-3 inhibitor J Cell Biochem.
26. Kulkarni N, Wei T, Schreiweis M, Brune K, Christopher T, Wolos J, Harvey A, Chandrasekhar S, Carozza M, Engler T, Martin T, Bryant H, Ma Y, Mitchell P, Hale J, Onyia J. 2006. Chondrogenic markers are expressed and regulated in bone and correlate with bone mass. Osteoarthritis Research Society International annual meeting. Prague Abstract 117.
27. Li G, Bunn JR, Mushipe MT, He Q, Chen X. 2005. Effects of pleiotrophin (PTN) over-expression on mouse long bone development, fracture healing and bone repair. Calcif Tissue Int 76:299-306.
28. Luo G, D'Souza R, Hogue D, Karsenty G. 1995. The matrix Gla protein gene is a marker of the chondrogenesis cell lineage during mouse development. J Bone Miner Res 10:325-334.
29. Mendler M, Eich-Bender SG, Vaughan L, Winterhalter KH, Bruckner P. 1989. Cartilage contains mixed fibrils of collagen types II, IX, and XI. J Cell Biol 108:191-197.
30. Murshed M, Schinke T, McKee MD, Karsenty G. 2004. Extracellular matrix mineralization is regulated locally; different roles of two gla-containing proteins. J Cell Biol 165:625-630.
31. Nah HD, Pacifici M, Gerstenfeld LC, Adams SL, Kirsch T. 2000. Transient chondrogenic phase in the intramembranous pathway during normal skeletal development. J Bone Min Res 15:522-533.
32. National Center for Biotechnology Information. 2005. http://www.ncbi.nlm. nih.gov.
33. Nicolas V, Mohan S, Honda Y, Prewett A, Finkelman RD, Baylink DJ, Farley JR. 1995. An age-related decrease in the concentration of insulin-like growth factor binding protein-5 in human cortical bone. Calcif Tissue Int 57: 206-212.
34. Olkku A, Bodine PVN, Linala-Kankkunen A, Mahonen A. 2004. Glucocorticoids induce glutamine synthetase expression in human osteoblastic cells: A novel observation in bone. Bone 34:320-329.
35. Oxlund H, Moskilde L, Ortoft G. 1996. Reduced concentration of collagen reducible cross links in human trabecular bone with respect to age and osteoporosis. Bone 19:479-484.
36. Poole KES, van Bezooijen RL, Loveridge N, Hamersma H, Papapoulos SE, Löwik CW, Reeve J. 2005. Sclerostin is a delayed secreted product of osteocytes that inhibits bone formation. FASEB J 19:1842-1844.
37. Rajani R, Meganck J, Goodsell R, Goldstein S, Hankenson KD. 2005. Acelerated fracture healing in thrombospondin 2 null mice. Trans Orthop Res Soc 30:768.
38. Rauvala H, Huttunen HJ, Fages C, Kaksonen M, Kinnunen T, Inai S, Raulo E, Kilpeläinen I. 2000. Heparin-binding proteins HB-GAM (pleiotrophin) and amphoterin in the regulation of cell motility. Matrix Biol 19:377-387.
39. Recker RR, Barger-Lux MJ. 2004. The elusive concept of bone quality. Curr Osteoporos Rep 2:97-100.
40. Reppe S, Stilgren L, Olstad OK, Brixen K, Nissen-Meyer LS, Gautvik KM, Abrahamsen B. 2006. Gene expression profiles give insight into the molecular pathology of bone in primary hyperparathyroidism. Bone 39:189-198.
41. Rubin CD. 2005. Emerging concepts in osteoporosis and bone strength. Curr Med Res Opin 21:1049-1056.
42. Rutter MM, Markoff E, Clayton L, Akeno N, Zhao G, Clemens TL, Chernausek SD. 2005. Osteoblast-specific expression of insulin-like growth factor-1 in bone of transgenic mice induces insulin-like growth factor binding protein-5. Bone 36:224-231.
43. Ryu J, Kim H, Lee SK, Chang E-J, Kim HJ. 2005. Proteomic identification of the TRAF6 regulation of vacuolar ATPase for osteoclast function. Proteomics 5:4152-4160.
44. Salasznyk RM, Westcott AM, Klees RF, Ward DF, Xiang Z, Vanderberg S, Bennett K, Plopper GE. 2005. Comparing the protein expression profiles of human mesenchymal stem cells and human osteoblasts using gene ontologies. Stem Cells Dev 14:354-366.
45. Srivastava AK, Vliet EL, Lewiecki EM, Maricic M, Abdelmalek A, Gluck O, Baylink DJ. 2005. Clinical use of serum and urine bone markers in the management of osteoporosis. Curr Med Res Opin 21:1015-1026.
46. Sutherland MK, Geoghegan JC, Yu C, Winkler DG, Latham JA. 2004a. Unique regulation of SOST, the sclerosteosis gene, by BMPs and steroid hormones in human osteoblasts. Bone 35:448-454.
47. Sutherland MK, Geoghegan JC, Yu C, Turcott E, Skonier JE, Winkler DG, Latham JA. 2004b. Sclerostin promotes the apoptosis of human osteoblastic cells: A novel regulation of bone formation. Bone 35:828-835.
48. Tare RS, Oreffo ROC, Clarke NMP, Roach HI. 2002. Pleiotrophin/Osteoblast- stimulating factor 1: Dissecting its diverse functions in bone formation. JBMR 17:2009-2020.
49. Van Bezooijen RL, Roelen BA, Visser A, van der Wee-Pals L, de Wilt E, Karperien M, Hamersma H, Papapoulos SE, ten Dijke P, Lowisk CW. 2004. Sclerostin is an osteocyte-expressed negative regulator of bone formation, but not a classical BMP antagonist. J Exp Med 199:805-814.
50. Van der Rest M, Garrone R. 1991. Collagen family of proteins. FASEB 5:2814-2823.
51. Wang D, Park JS, Chu JSF, Krakowski A, Lou K, Chen DJ, Li S. 2004. Proteomic profiling of bone marrow mesenchymal stem cells upon transforming growth factor beta1 stimulation. J Biol Chem 279:43725-43734.
52. Winkler DG, Sutherland MK, Geoghegan JC, Yu C, Hayes T, Skonier JE, Shpektor D, Jonas M, Kovacevich BR, Staehling-Hampton K, Appleby M, Brunkow ME, Latham JA. 2003. Osteocyte control of bone formation via sclerostin, a novel BMP antagonist. EMBO J 22: 6267-6276.
53. Wu JJ, Eyre DR. 1995. Structural analysis of cross-linking domains in cartilage type XI collagen. Insights on polymeric assembly. J Biol Chem 270:18865-18870.